New era for ME/CFS research as top cytokine study attracts media headlines
The immune systems of patients who have recently developed ME/CFS look markedly different from those who have been ill for much longer, according to a major new study from Drs. Ian Lipkin and Mady Hornig at Columbia University. This shift in immune function hadn’t been seen before.
Discuss the article on the Forums.

Antiviral Letermovir for cmv

Discussion in 'Other Health News and Research' started by heapsreal, Feb 24, 2014.

  1. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    7,674
    Likes:
    5,415
    australia (brisbane)
    This antiviral doesnt seem to far from being approved and seems to be more effective then valcyte and less side effects, so they say.
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807861/

    Novel therapies are urgently needed for the management of cytomegalovirus (CMV) disease in high-risk patients. Currently licensed agents target the viral DNA polymerase, and although they are effective, they are fraught with toxicities to patients. Moreover, emergence of antiviral resistance is an increasing problem, particularly for patients on long-term suppressive therapy. A new agent, letermovir (AIC246), shows great promise for the management of CMV infection. Advantages include its good oral bioavailability, its lack of toxicity, and the apparent absence of drug-drug interactions. Letermovir has a novel mechanism of action, exerting its antiviral effect by interfering with the viral pUL56 gene product and in the process disrupting the viral terminase complex. This agent demonstrates substantial promise as an alternative to more toxic antivirals in patients at high risk for CMV disease, particularly in the transplantation setting.
     

See more popular forum discussions.

Share This Page